Clinical Trials
211 trialsFHAMe
University of Toronto
Gemcitabine, Carboplatin, and Lenalidomide for Treatment of Advanced/Metastatic Urothelial Cancer and Other Solid Tumors
National Institutes of Health Clinical Center (CC)
TraveraRTGx
Travera Inc
ESPERANZA: External Control Arm Study for T-DXd for Patients With HER2 IHC3+ Solid Tumors
AstraZeneca
Study of DF6215 in Patients With Advanced Solid Tumors
Dragonfly Therapeutics
Pembrolizumab (Anti-PD-1) and AMG386 (Angiopoietin-2 (Ang-2) in Patients With Advanced Solid Tumor
Dana-Farber Cancer Institute
MiGHT
University of Michigan Rogel Cancer Center
CATALYST
Rutgers, The State University of New Jersey
Genetic Analysis of Blood and Tissue Samples From Patients With Advanced Cancer, Moonshot Study
National Cancer Institute (NCI)
PREPARE
Institut Bergonié
A Phase 1 in Patients With HLA-A*0201+ and WT1+ Recurrent/Metastatic Cancers
Cue Biopharma
Remote Telemonitoring of Patient-Generated Physiologic Health Data and Patient-Reported Outcomes
City of Hope Medical Center
INOVOLINE
Hospices Civils de Lyon
Drug Intensive Monitoring Study of Olaparib in Clinical Practice Among Chinese Patients
AstraZeneca
Study of ESG401 in Adults With Solid Tumors
Shanghai Escugen Biotechnology Co., Ltd
FIDURA
Sahlgrenska University Hospital
EARN
Washington University School of Medicine
A Phase 1/2, Open-Label, Dose-Escalation, Safety Study of INCAGN01949 in Subjects With Advanced or Metastatic Solid Tumors
Incyte Corporation
GLIMMER-01
Palleon Pharmaceuticals, Inc.
Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of INCAGN01876 Combined With Immune Therapies in Advanced or Metastatic Malignancies
Incyte Corporation
OLAP
AstraZeneca
KEYVIBE-005
Merck Sharp & Dohme LLC
Clinical Trial of Metastasis Inhibitor NP-G2-044 in Patients With Advanced or Metastatic Treatment-Refractory Solid Tumor Malignancies
Novita Pharmaceuticals, Inc.
INCB106385 Alone or in Combination With Immunotherapy in Advanced Solid Tumors
Incyte Corporation
PRIORITY
Institut Bergonié
A Study of CDX-585 in Patients With Advanced Malignancies
Celldex Therapeutics
Study of NGM120 in Subjects With Advanced Solid Tumors, Pancreatic Cancer, and Prostate Cancer Using Combination Therapy
NGM Biopharmaceuticals, Inc
Dose Escalation of RMC-5552 Monotherapy in Relapsed/Refractory Solid Tumors
Revolution Medicines, Inc.
PREFER
Labcorp Corporation of America Holdings, Inc
PRISMS
UNC Lineberger Comprehensive Cancer Center
Health Care Coach Support in Reducing Acute Care Use and Cost in Patients With Cancer
Stanford University
REMOVE
Lindis Bloodcare GmbH
ROOT
Taproot Health
ACE1702 in Subjects With Advanced or Metastatic HER2-expressing Solid Tumors
Acepodia Biotech, Inc.
Study of Continuous OSI-906 Dosing
Astellas Pharma Inc
Study of Intermittent OSI-906 Dosing
Astellas Pharma Inc
Development and Validation of a Prediction Model for AKI Following Cisplatin-Based HIPEC in Patients With Ovarian Cancer
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
IVY
Eli Lilly and Company
A Bioequivalence Study Between the Proposed and Current Talazoparib Capsule Formulation and Food Effect Study for the Proposed Talazoparib Capsule Formulation in Participants With Advanced Solid Tumors
Pfizer
AURA
UNC Lineberger Comprehensive Cancer Center
Pharmacogenomics Testing in the Optimal Use of Supportive Care Medications in Stage III-IV Cancer
Mayo Clinic
Assessments of Genetic Counseling Augmented With an Educational Video or Pamphlet Versus Traditional Counseling
Stanford University
RADIANT
DxTerity Diagnostics
A Study to Evaluate the Safety and Tolerability of Immunotherapy Combinations in Participants With Advanced Malignancies
Arcus Biosciences, Inc.
CATCH-R
pharmaand GmbH
Study of Cabozantinib (XL184) in Adults With Advanced Malignancies
Exelixis
At-Home Research Study for Patients With Autoimmune, Inflammatory, Genetic, Hematological, Infectious, Neurological, CNS, Oncological, Respiratory, Metabolic Conditions
Sanguine Biosciences
A Study of CDX-1140 (CD40) as Monotherapy or in Combination in Patients With Advanced Malignancies
Celldex Therapeutics
A Study of hSTC810 With Advanced/Metastatic Solid Tumors (STCUBE-001)
STCube, Inc.
OPT-IN
Dana-Farber Cancer Institute